A61K 31/13
Amines
Official title: Amines {(A61K31/04 takes precedence)}
A61K31/13 (Amines) appears on 11,104 US grants and 19,581 published applications in this corpus.
Search patents in A61K- Granted patents
- 11,104
- Published applications
- 19,581
- Assignees
- 6,173
- Inventors
- 28,167
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 57 | 0 |
| 1977 | 83 | 0 |
| 1978 | 35 | 0 |
| 1979 | 22 | 0 |
| 1980 | 35 | 0 |
| 1981 | 38 | 0 |
| 1982 | 36 | 0 |
| 1983 | 33 | 0 |
| 1984 | 41 | 0 |
| 1985 | 35 | 0 |
| 1986 | 35 | 0 |
| 1987 | 30 | 0 |
| 1988 | 29 | 0 |
| 1989 | 63 | 0 |
| 1990 | 62 | 0 |
| 1991 | 65 | 0 |
| 1992 | 59 | 0 |
| 1993 | 80 | 0 |
| 1994 | 69 | 0 |
| 1995 | 85 | 0 |
| 1996 | 124 | 0 |
| 1997 | 149 | 0 |
| 1998 | 184 | 0 |
| 1999 | 206 | 0 |
| 2000 | 189 | 0 |
| 2001 | 252 | 90 |
| 2002 | 240 | 330 |
| 2003 | 215 | 525 |
| 2004 | 155 | 553 |
| 2005 | 123 | 566 |
| 2006 | 188 | 542 |
| 2007 | 101 | 524 |
| 2008 | 113 | 513 |
| 2009 | 114 | 533 |
| 2010 | 186 | 635 |
| 2011 | 218 | 654 |
| 2012 | 286 | 709 |
| 2013 | 392 | 764 |
| 2014 | 476 | 979 |
| 2015 | 502 | 1083 |
| 2016 | 600 | 1120 |
| 2017 | 593 | 1070 |
| 2018 | 562 | 913 |
| 2019 | 585 | 987 |
| 2020 | 555 | 1063 |
| 2021 | 558 | 1134 |
| 2022 | 541 | 1063 |
| 2023 | 482 | 948 |
| 2024 | 444 | 945 |
| 2025 | 458 | 722 |
| 2026 | 321 | 616 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Ketamine formulation6 Oct 2026US 12,751,918 B2Fresenius Kabi USA, LLC
- Parenteral treatments involving aminoadamantane derivatives6 Oct 2026US 12,751,934 B2Shinkei Therapeutics, Inc.
- Method of treating and ameliorating depression6 Oct 2026US 12,751,935 B2The United States Government as represented by the Department of Veterans Affairs
- Topical anaesthetic composition having improved vasoconstrictor stability6 Oct 2026US 12,751,946 B2Animal Ethics Pty Ltd
- Combination drug for the control and management of type 2 diabetes mellitus6 Oct 2026US 12,751,958 B2Laboratorios Silanes S.A. de C.V.
- Esketamine formulations and methods for preparation and storage8 Oct 2026US 2026/0306360 A1Janssen Pharmaceutica NV
- Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity8 Oct 2026US 2026/0306403 A1Bs Biotechna Spolka Akcyjna
- Compounds and combinations thereof for treating neurological and psychiatric conditions8 Oct 2026US 2026/0306426 A1Antecip Bioventures II LLC
- Compositions, methods of treatment, and containers including compositions8 Oct 2026US 2026/0306427 A1
- Methods of preventing post-traumatic osteoarthritis using metformin8 Oct 2026US 2026/0306428 A1
Most cited
By later US patents
- Anti-angiogenic compositions and methods of use968US 5,716,981 AAngiogenesis Technologies, Inc. · 1998
- Therapeutic inhibitor of vascular smooth muscle cells562US 5,733,925 ANeoRx Corporation · 1998
- Preparation of particles for inhalation553US 5,985,309 AMassachusetts Institute of Technology · 1999
- Particles incorporating surfactants for pulmonary drug delivery537US 5,855,913 AMassachusetts Instite of Technology · 1999
- Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine486US 10,299,720 B2The General Hospital Corporation · 2019